T1	Participants 121 189	patients <65 years with poor prognosis histologically aggressive NHL
T2	Participants 212 224	457 patients
T3	Participants 316 504	patients with poor prognosis histologically aggressive non-Hodgkin lymphoma (NHL) showing a response to initial CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy
